At BDSRA, we do more than impact the drug development process and regulatory pathway - we have contributed to a strong foundation of research tools like assays, bio samples, cell lines, and natural history, that are used as the building blocks for many scientific projects
in different stages. Facilitating the creation of tools that speed up the prediscovery and preclinical stages of developing a treatment is a unique asset our community provides.
Because of your time and treasure, we have grown to a place where multiple clinical trials are on the horizon and many more research projects are being done. We have and are continuing to change the course of the disease through our work.
Each year, BDSRA invites proposals from over 200 scientists working in the field to fund the most promising basic and translational (moving to clinical trial) research. Each proposal is peer-reviewed by experts in lysosomal diseases at universities, children's hospitals and in the pharmaceutical industry to provide well-rounded reviews. This year's focus was on Biomarkers.
We are honored to partner with
Drew's Hope and Noah's Hope/Hope4Bridget to fund this year's awardees:
Dr. David Sleat
from Rutgers, The State University of New Jersey working in CLN2 on a project entitled
Blood-based biomarker discovery for LINCL.
Dr. Erika Augustine from
University of Rochester Medical Center
working in CLN3 on a project entitled
Developing Neuroimaging Biomarkers of Progression for CLN3 Disease.
Dr. Trevor McGill from Oregon Health & Science University working in CLN7 on a project entitled Retinal autofluorescence as a biomarker of disease progression and treatment efficacy in a non-human primate model of CLN7 Batten disease.
Dr. Wendy E Heywood from University College London working CLN2 on a project entitled Biomarkers for CLN2 Disease Treatment Monitoring and Disease Severity.